Genetic variations in genes involved in repairing platinum-induced DNA lesions may contribute to the toxicity of platinumbased chemotherapy. The role of single-nucleotide polymorphisms (SNPs) within DNA repair pathways in the occurrence of severe toxicity is not yet understood. Current studies prefer to do original works rather than analyze previously published data. Our study aimed to replicate associations between previously investigated SNPs and toxicities and to identify new genetic makers. We systematically examined the relevance of 97 SNPs in 54 candidate genes responsible for repairing DNA interstrand and intrastrand cross-links to severe toxicity in a discovery cohort of 437 NSCLC patients receiving platinum-based chemotherapy. Statistically significant SNPs were then assessed for replication in an independent validation cohort of 781 NSCLC patients. We found that 7 SNPs were significant at p < 0.01 (RRM1 rs12806698, XPC rs2228000, XPF rs1799801, hMLH1 rs1800734, PMS2 rs1062372, REV3L rs462779 and FANCC rs4647554) in the discovery cohort. Among them, two SNPs (RRM1 rs12806698 and hMLH1 rs1800734) remained significant after Bonferroni correction. XPC rs2228000 showed a significant relationship with severe gastrointestinal toxicity in the validation cohort. When the two cohorts were combined, XPC rs2228000 presented better tolerance of severe hematologic toxicity, gastrointestinal toxicity and leukopenia (OR 5 0.677, 95% CI: 0.510-0.899, p 5 0.007; OR 5 0.565, 95% CI: 0.368-0.869, p 5 0.009; OR 5 0.628, 95% CI: 0.439-0.899, p 5 0.011, respectively). Our findings can offer comprehensive pharmacogenetic information for platinum-induced toxicities.
the cytotoxic effects of platinum lack of specificity, a wide range of toxicity inevitably accompany during the treatment. According to a large random clinical trial in 1183 advanced NSCLC patients, the incidence of total grade 3-5 (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE]) toxicity was 30.4%. Grade 3-5 myelosuppression and gastrointestinal toxicity were most commonly observed, including neutropenia (22.8%), anemia (5.6%), thrombocytopenia (5.8%), nausea (8.0%) and vomiting (7.4%), while the incidence of grade 3-5 renal toxic effects and neuropathy were 1.2% and 2.5%, respectively. 2 The occurrence of severe toxicity varied depending on the type of chemotherapy regimens or adjuvant drugs given along with. For example, patients treated with cisplatin and gemcitabine were more likely to exhibit severe myelosuppression than those treated with cisplatin plus paclitaxel. 2 Large individual variability exists in the severity of platinum-induced toxicities. For example, severe myelosuppression that leads to dose reduction or treatment termination may occur in 20-40% of patients, while other patients may be marginally affected. 3 Furthermore, toxic effects may have some links to drug dose. The absence of toxicity might suggest underdosing and hence unsatisfactory therapeutic results. 4, 5 Therefore, it is hypothesized that if biomarkers could be identified to predict severe toxicity, doses could be adjusted according to the severity of toxicity and preventive interventions could be determined in advance. It is reported that DNA damage repair capacity may affect the substantial variability in toxicity since suboptimal DNA repair results in the removal of fewer DNA lesions and increased cytotoxicity to platinum. Previously published pharmacogenetic articles mainly focused on genetic variants in the nucleotide excision repair (NER) pathway, 6 as it is responsible for repairing DNA intrastrand cross-links. The most commonly reported candidate genes associated with toxicity include ERCC1, 7 XPD, 8 RRM1 9 and XRCC1. 10, 11 However, most studies are carried out in small sample size with a restricted number of genetic polymorphisms and commonly absence of a replication strategy. These results were inconsistent, and no definite alleles have been identified to be clinically relevant. Platinum agents can bind with DNA to cause intrastrand and interstrand cross-links, which are the root cause of their cytotoxic effects. The DNA lesions caused by platinum are predominantly intrastrand cross-links, while interstrand cross-links account for a small portion of the lesions (1-3%). It is thought that interstrand cross-links can do more harm to DNA replication and transcription than intrastrand crosslinks; therefore, fewer interstrand cross-links may also contribute greatly to the toxicity of platinum agents. 12 Complex DNA repair pathways participate in resolving DNA interstrand cross-links, including translesion DNA synthesis (TLS), the Fanconi anemia (FA) pathway and homologous recombination (HR), thus regulating the cellular response to cisplatin. [13] [14] [15] Recent studies have revealed novel roles of base excision repair (BER) and mismatch repair (MMR) pathways in activating interstrand cross-links and therefore modulating cisplatin cytotoxicity rather than activating damage repair. 16 Genes involved in those pathways are highly polymorphic; however, whether single nucleotide polymorphisms (SNPs) in those pathways influence the platinum-induced toxicity in NSCLC patients remains unknown.
As no well-organized clinical protocol has validated these previously investigated SNPs and there is still a lack of comprehensive studies regarding the association of genetic variations in DNA repair pathways with platinum-induced toxicities in NSCLC patients, we conducted a multiple-center, two-stage analysis to identify markers associated with severe platinum-induced toxicity in NSCLC patients. The aims of this study were as follows: (1) to validate the previously studied SNPs in a cohort of NSCLC patients and (2) to analyze the association of new variations in DNA repair pathways with severe platinum-induced toxicity.
MATERIAL AND METHODS

Study approval
The study protocol was approved by the Ethics Committee of Xiangya School of Medicine, Central South University (registration number: CTXY-110008-1). The clinical research registration was approved by the Chinese Clinical Trial Registry (registration number: ChiCTR-RNC-12002892; http://www. chictr.org.cn/showproj.aspx?proj5 6662).
Study population
Four hundred and thirty-seven patients in the discovery cohort were recruited from Xiangya Hospital and Hunan What's new? Cisplatin or carboplatin in combination with another cytotoxic drug has been recommended as first-line chemotherapy in lung cancer. Platinum agents can however cause cytotoxic effects through their binding with DNA. Genetic variations in DNA repair genes may contribute to the toxicity of platinum-based chemotherapy, but previous pharmacogenetic studies have been conflicting and inconclusive. Here, the authors performed a multiple-center, two-stage analysis to examine the association of 97 SNPs in 54 genes from DNA repair pathways with severe platinum-induced toxicities. They demonstrated that XPC rs2228000 conferred better tolerance toward severe toxicities. The findings may offer comprehensive pharmacogenetic information for platinum-induced toxicity.
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Province Tumor Hospital, Changsha, Hunan, China, from 2012 to 2013. Seven hundred and eighty-one patients recruited from other hospitals (Shanghai Chest Hospital, Zhongshan Hospital and Changhai Hospital) from 2005 to 2010 were used as the validation cohort.
All the patients in this study belong to Chinese south population and share genetic homogeneity. The eligible patients were required to meet the following criteria: age between 18 and 80 years; histologically or cytologically confirmed NSCLC at stage IIIA, IIIB or IV; a good performance status (Eastern Cooperative Oncology Group [ECOG] 2) that can tolerate chemotherapy; and no prior history of surgery, chemotherapy or radiotherapy. Those patients with serious concomitant diseases that might greatly affect their physical condition were excluded.
Demographic data (age, smoking status, gender, ECOG value, histologic types and TNM [tumor node metastasis] stage), treatment information and clinical data (physical examination, routine urine and blood tests) were obtained from the medical records or through inquiry. Written informed consent was obtained from each patient.
Treatments
All patients received first-line platinum-based chemotherapy regimens consisting of cisplatin or carboplatin plus a cytotoxic drug (gemcitabine, pemetrexed, paclitaxel, docetaxel or navelbine) for 2-6 cycles of treatment. The doses of chemotherapy regimens in the discovery and validation cohorts were exactly the same according to the NCCN guidelines, including cisplatin (75 mg/m 
Toxicity evaluation
Toxicities were evaluated and graded according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE 3.0). Patients who suffered from severe toxicity were defined by the occurrence of grade 3 or 4 adverse events. Our study concentrated on severe toxicity during 2-6 cycles of first-line platinum-based chemotherapy. The most severe toxicity symptoms, including leukocytopenia, neutropenia, thrombocytopenia, anemia, nausea, vomiting, nephrotoxicity, neurotoxicity and ototoxicity, were recorded for data analyses. The occurrence of neutropenia, leukopenia, anemia or thrombocytopenia indicated hematologic toxicity, while gastrointestinal toxicity was characterized as nausea or vomiting.
Selection of SNPs and genotyping
The selection of previously investigated SNPs was based on published literatures in PubMed and SpringerLink. We systematically reviewed studies that reported associations between genetic variations in DNA repair pathways and toxicity (ototoxicity, nephrotoxicity, neurotoxicity, myelosuppression, nausea and vomiting). We focused on SNPs with potential functional effects rather than tagSNPs. Studies were excluded from the analysis if the toxicity evaluation criteria were absent or not elaborated. We also excluded articles, in which the data were not sufficient to prove the association. The latest literature in our systematic review was published on August 2016.
For the selection of new SNPs with potential functional significance, we compiled a list of 54 candidate genes in 6 DNA repair pathways previously known to respond to platinum-based lesions, including nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous recombination (HR), translesion DNA synthesis (TLS) and the Fanconi anemia (FA) pathway. 17 Genomic DNA from all subjects was isolated from a peripheral blood sample using a FlexiGene DNA Kit (Qiagen, Hilden, Germany) and stored at 2208C until use. Genotyping was conducted using the Sequenom MassARRAY system (Sequenom, San Diego, CA).
Statistical analyses
The frequencies of clinical parameters and occurrence rate of severe toxicities in two cohorts were compared using a chi-squared test or Student's t test. Fisher's exact test was used to examine the Hardy-Weinberg equilibrium (HWE). Logistic regression with stepwise selection was utilized to select clinical covariates of potential effects. Covariates declared as significant were included in the multivariate analysis. The influences of genetic variants on the occurrence of severe toxicity were examined using multivariable logistic regression by calculating odds ratios (ORs) and their 95% confidence intervals (CIs). For each SNP, three different genetic models (additive, dominant and recessive) were analyzed, and the model with lowest p values was considered the best-fitting model. SNPs declared as most significant with various kinds of toxicity were evaluated in the subsequent validation cohort. The p values were two-sided, and p < 0.05 was considered statistically significant. We apply Bonferroni correction for multiple testing. The statistical analyses were carried out using Plink (Version 1.07, http://pngu.mgh.harvard.edu/purcell/plink/) and/or SPSS 19.0 (SPSS Inc., Chicago, IL).
RESULTS
Results of SNP selection and genotyping
We identified 21 relevant publications (Supporting Information, Table 1 ), most of which focused on hematologic toxicity and gastrointestinal toxicity. A small portion of the studies also investigated specific hematologic toxicity, such as leukocytopenia, neutropenia, thrombocytopenia and anemia. Toxicity assessments were graded mostly using CTCAE 3.0, and the majority of the studies compared the occurrence of grade 3-4 toxicity with grade 0-2 toxicity, the same classification as we have used in this study. We identified 39 SNPs that had been previously investigated for an association with toxicity (Supporting Information, Table 2 ), and 24 of these SNPs were selected for genotyping. Fifteen SNPs were not included in the analysis because of a low minor allele frequency, no existence in Asian populations or locating in the intron area. In addition, we selected 73 new SNPs with definite biological functions or having potential to influence the function of expressed proteins. All of them have never been studied in published literatures regarding platinum-induced toxicities.
In total, 97 SNPs were selected for genotyping. SNPs with a genotyping call rate <95% and those that deviated from HWE (p < 0.05) were excluded from the final analysis. As a result, 82 SNPs were included in the final analysis. The observed allele frequency for the selected SNPs was in agreement with the MAF in the Chinese or Asian populations. The detailed information on these SNPs is summarized in Supporting Information, Table 3 .
Characteristics of study populations
The demographic characteristics of the discovery and validation cohorts are summarized in Table 1 . Both studies included a Chinese south population, but the two study populations had some differences in the distribution of age, gender, histologic type, TNM stage and chemotherapy regimen. The mean age of patients in the discovery cohort was younger than that in the validation cohort (55.1 6 9.5 years in the discovery cohort vs 57.6 6 9.8 years in the validation cohort). The distribution of gender was different between the two cohorts (the percentage of male patients was 76.9% in discovery cohort and 71.4% in validation cohort). A relatively higher proportion of squamous cell tumors was observed in the discovery cohort (42.3% vs 21.9%), while adenocarcinoma tumors were more common in the validation cohort (50.1% vs 64.3%). The constituent ratio of the chemotherapy regimen was quite diverse between the two cohorts.
The incidence of severe hematologic toxicity, gastrointestinal toxicity and neutropenia in the discovery cohort was 24.0%, 8.7% and 16.0%, respectively, which was quite similar to that of the validation cohort (24.6%, 8.1% and 12.3%, respectively; Table 2 ). Severe leukocytopenia occur more frequently in validation cohort (16.8% vs 10.1%), while severe thrombocytopenia (5.9% vs 3.2%) and severe anemia (7.3% vs 3.3%) were more common in the discovery cohort than that in the validation cohort ( Table 2 ). Considering that the incidence of severe neurotoxicity, hepatotoxicity, nephrotoxicity and ototoxicity were quite low (2.7%, 0.7%, 0.7% and 0.9%, respectively), we did not include those toxicities in the subsequent association analyses.
The detailed characteristics of the discovery and validation cohorts are described in Supporting Information, Tables 4  and 5 , respectively.
Replication of previously investigated SNPs
We initially tested the 24 SNPs that were identified from previous publications. 13 SNPs reached statistical significance at the p < 0.05 level (Table 3) . Three SNPs (RRM1 rs12806698, XPC rs2228000 and XPF rs1799801) showed a strong association with severe toxicities (p < 0.01). Among them, 4 SNPs (ERCC1 rs11615, RRM1 rs12806698, XPC rs2228001 and XRCC1 rs25487) were reported to be associated with toxicity in previous publications. 
Results of new SNPs
In a second series of analyses on new SNPs, a total of 15 SNPs reached statistical significance at the p < 0.05 level (Table 4) . Those SNPs are mainly located in the MMR, TLS, HR and FA pathways, and 4 of these SNPs were significant at p < 0.01(hMLH1 rs1800734, PMS2 rs1062372, REV3L rs462779 and FANCC rs4647554). The association of hMLH1 rs1800734 with a decreased risk of severe leukocytopenia remained significant after Bonferroni correction (OR The full results in the discovery cohort are presented in Supporting Information, Table 6 .
Validation of SNPs with most significance
Three SNPs (XPC rs2228000, PMS2 rs1062372 and FANCC rs4647554) that showed the most significance with more than one kind of toxicity were selected to be analyzed in the validation cohort. XPC rs2228000 was significantly associated with severe gastrointestinal toxicity in the validation cohort. Table 5 ). FANCC rs4647554 showed a slightly increased risk of severe anemia in the validation cohort (OR 5 3.039, 95% CI: 1.007-9.167, p 5 0.049; Supporting Information, Table 7 ) and severe hematologic toxicity in the combined cohort (OR 5 1.509, 95% CI: 1.032-2.206, p 5 0.034). Considering the call rate of the SNP in validation was 83.8%, we think that the positive result in the validation cohort does not have adequate statistical power.
Although the significant association of PMS2 rs1062372 could not be observed in the validation cohort, PMS2 rs1062372 had the same trend toward a lower percentage of severe toxicity (Supporting Information, Table 8 ).
DISCUSSION
Individual variability in platinum-induced toxicity necessitates the identification of genetic markers. Current studies prefer to do original works rather than analyze previously published findings. We conducted a follow-up study regarding the reproducibility of such previous published SNPs within DNA repair pathways. In addition, we evaluated new variants with potential biological functions in relevant DNA repair genes. We found 7 SNPs that were significant at p < 0.01 (RRM1 rs12806698, XPC rs2228000, XPF rs1799801, hMLH1 rs1800734, PMS2 rs1062372, REV3L rs462779 and FANCC rs4647554) in the discovery cohort. Among them, 2 SNPs (RRM1 rs12806698 and hMLH1 rs1800734) remained significant after applying the Bonferroni correction. XPC rs2228000 showed a significant association with severe gastrointestinal toxicity in the validation cohort. When the two cohorts were combined, XPC rs2228000 presented better tolerance of severe hematologic toxicity, gastrointestinal toxicity and leukopenia.
Over the past decades, many studies have evaluated genetic variants in DNA repair genes for an association with platinuminduced toxicity. We completed a comprehensive review of previously published articles (Supporting Information, Table 1 ) and identified 21 studies regarding platinum-induced toxicity. Those studies have the following discrepancies: (1) Most studies were performed with an inadequate sample size (most articles used no more than 200 patients), different races (Chinese, 8, 11 American, 7 Italian 18 and Spanish [19] [20] [21] ), various tumor types (NSCLC, 7,18 SCLC, 11, 22 ovarian cancer, 23, 24 head and neck squamous cell cancer, 25 malignant mesothelioma 26 and bladder cancer 27 ), and diverse regimens (different drug combinations, different doses or chemoradiotherapy involved 6, 7, 25, 27 ). (2) The 
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occurrence of the toxicities in previous studies was quite variable. ( 3) The majority of articles had a dichotomy in the toxicity grades, where most articles compared the occurrence of grade 3-4 toxicity with that of grade 0-2 toxicity, while other articles compared toxicities in classifications including grade 0-3 versus grade 4 toxicity, 23 grade 0-1 versus grade 2-4 toxicity, 19, 25, 26, 28 and grade 0 versus grade 1-4 toxicity. 20, 22, [29] [30] [31] [32] (4) A part of study only used a chi-squared test to assess the distribution of genotypes in different groups rather than using multivariate logistic regression to calculate the adjusted OR. 19, 27 Considering the above facts, it makes sense that the results from previous studies were usually inconsistent with regard to the same variants.
Our study systematically analyzed the reproducibility of those previous findings by applying strict criteria to control for potential confounding facts. In total, we investigated 24 previously studied SNPs from 17 genes, in which 9 SNPs were previously reported to have a significant association with toxicity in either an increased or decreased direction. Twelve previously investigated SNPs showed a significant relationship with severe toxicities in the discovery cohort. Four SNPs (ERCC1 rs11615, RRM1 rs12806698, XPC rs2228001 and XRCC1 rs25487) showed the same trend in line with the previous research. RRM1 rs12806698 (237C > A) is the most significant genetic variant that is associated with an increased risk of severe leukocytopenia, and in a study by Zhang, this SNP has also been described as a risk factor for overall grade 3-4 toxicity and vomiting in 388 patients with stage IIIB and IV NSCLC. 9 Two important variants in ERCC1 (rs11615 and rs3212986) have been proposed to change an amino acid of a protein or affect mRNA stability. The ERCC1 gene variant rs11615 (Asn118Asn) has been described by P erez-Ram ırez as being associated with an increased risk of increased grade 3-4 overall toxicity. 21 In our data, rs11615 also shows an association with an increased risk of severe anemia, along the same trend as P erez-Ram ırez's results. Although ERCC1 rs3212986 (C8092A) did not seem to affect toxicity risk in most previous studies, 6, 21, 24 this variant played a protective role in hematologic toxicity in our study.
XPC cooperates with RAD23B to detect DNA lesions and recruit subsequent NER proteins. 33 High XPC expression can lead to resistance to cisplatin in lung adenocarcinoma cell lines. 34 XPC rs2228000 (Ala499Val) and XPC rs2228001 (Lys939Gln) can cause missense mutation in the coding region. The variant allele of Lys939Gln can impair DNA repair capacity, while the variant allele of Ala499Val is associated with an increased DNA repair capacity. 35 One article demonstrated that XPC rs2228001 was associated with an increased risk of grade 3-4 hematological toxicity of chemoradiotherapy in patients with bladder cancer. 27 In our data, rs2228001 also showed an association with an increased risk of more than one type of hematologic toxicity. XPC rs2228000 was associated with a low risk of severe toxicities in the discovery cohort and the validation cohort. The association of this SNP with decreased toxicity in our study was in accordance with its biological functions related to increased DNA repair capacity, which can protect normal cells against the cytotoxicity of platinum agents.
XRCC1 rs25487 (Arg399Gln) was commonly reported to be associated with increased risk of overall grade 3-4 toxicity and grade 3-4 gastrointestinal toxicity. 11 This association was also seen in our study. RAD51 is the central player in the beginning of the HR pathway and is involved with resistance to platinum agents. RAD51 rs1801320 is located in the 5 0 -UTR region. The substituted G is significantly associated with enhanced promoter activity. 36 Our study found that RAD51 rs1801320 was significantly associated with a decreased risk of severe hematologic toxicity. These findings cannot be reasonably explained by the decreased activity of the RAD51 protein. However, our results are analogous to previous findings showing that RAD51 rs1801320 was associated with a reduced incidence of radiation pneumonitis. 37 Limited studies have been concerned with polymorphisms in BER genes. We further expanded the screening range by selecting more SNPs within candidate genes in the BER pathway. A decreased risk of severe hematologic toxicity was found for APE1 rs1130409, APE1 rs2307486 and MUTYH rs3219489. A similar finding was reported in a Russian population and showed that the heterozygous genotype of MUTYH rs3219484 had a decreased risk of severe neutropenia. 38 APE1 and MUTYH are both multifunctional enzymes involved in repairing oxidative DNA damage. 39 The observed association may emphasize a substantial role of BER pathway in oxidative stress as cisplatin can mediate the apoptosis of normal cells through the generation of reactive oxygen species (ROS). 40 Relatively, few studies have focused on the DNA repair pathways responding to platinum-induced interstrand crosslinks. MMR pathway was composed of several proteins such as hMLH1, hMSH2, PMS2, working together to recognize platinum-induced interstrand DNA cross-links and transmit apoptotic signals. 16 MMR deficiency caused by methylation in the hMLH1 promoter region may lead to cisplatin resistence. 41 hMLH1 rs1800734 (-93G > A) shows a strong association with decreased risk of severe leukocytopenia in our study. This variant in the promoter region of hMLH1 may affect binding or methylation thus affecting risk of toxicty. 42 TLS can guarantee the completion of DNA replication when high-fidelity enzymes are stalled at sites of DNA damage. This process is mediated by multiple low-fidelity polymerases to bypass DNA lesions, among which REV1 and Pol f (constituted by subunits REV3 and REV7) function in the resolution of platinum interstrand lesions. 43 REV3L rs462779 and REV7 rs2233006 show a slight association with toxicity in our study. Two studies investigated genetic variants in TLS pathway for their contribution to platinum-induced toxicity. Shao et al. discovered that several SNPs in POLK (coding gene of Pol j) were associated with platinum-induced severe toxicity. 44 Ye et al. divided patients according to smoking status, genotyped 13 tagSNPs of REV3 and REV7 and found that the five SNPs were correlated with an increased risk of grade 3 or 4 hematologic toxicity. 45 The FA pathway is composed of a series of FA-associated proteins working cooperatively on a signaling pathway that is critical for repairing interstrand cross-links. Monoubiquitination of FANCD2/I is a central step, followed by recruiting endonucleases to activate the FA network. 13 FANCC rs4647554, FANCF rs3740615, FANCF rs4442551, FANCJ rs2048718 and FANCM rs3776332 showed some relations with severe toxicity in our study. This is the first study to identify the association between polymorphisms in FA genes and severe platinum-induced toxicity in NSCLC patients. Another analogous study on taxane-induced neurotoxicity in breast cancer patients in which SNPs in FANCD2 were associated with an increased risk of grade 3 or 4 neurological toxicity has been published. 46 A previous study found that the depletion of FANCF can inhibit FANCD2 monoubiquitination and enhance the sensitivity to cisplatin. 47 It is not by chance that we found SNPs in the FA pathway were predictive of platinum-induced toxicity.
As the genetic basis in platinum-based therapy is much complicated, in addition to DNA repair pathway, the process of influx, 48 detoxification and apoptosis may also exert influences on the effect of platinum agents. 39 Single DNA biomarker may exhibit a slight effect on the clinical outcome. 39 Recently, a genome-wide association study (GWAS) was used to identify the genetic determinants of platinum-induced myelosuppression. 49 Unlike the dichotomized classification by the occurrence of grade 3-4 myelosuppression in previous studies, the GWAS used ordinal logistic regression to analyze the association of the myelosuppression grade with SNPs. Another study used whole-exome sequencing to identify genetic markers for grade 3-4 neutropenia and thrombocytopenia in gemcitabine/carboplatin chemotherapy. 50 The two studies identified several genetic markers related with myelosuppression risk, but there is a lack of functional studies and the results have not be analyzed or replicated in other studies. Again, no definitive associations have been found.
Compared with previous studies, the major strengths of our study lie in its relatively large sample size, the validation cohort that was used and the comprehensive panel of potentially functional SNP that may affect protein expression or function. In addition, we collected more detailed clinical toxicity data, whereas other previous studies analyzed the overall hematologic toxicity or merely focused on single type of toxicity such as leukocytopenia or neutropenia. 20, 23 Meanwhile, we accurately defined the phenotype. The rates of toxicities in our study were quite similar to those previously reported in large randomized clinical trials. 2 The limitation of our study is that all the patients in our study received combination chemotherapy. Different nonplatinum drugs in chemotherapy regimens can affect toxicity profiles. In spite of a comparatively large sample size, our study may have an inadequate statistical power in regard to toxic effects with low frequency, such as thrombocytopenia, anemia and gastrointestinal toxicity. Furthermore, variants in our study were associated with limited number of toxicity, but fail to show significant effect to other toxicities. Further study should focus on applying meta-analysis to increase the statistical power.
Our study comprehensively analyzed the association of genetic variants in candidate genes that repair platinuminduced DNA interstrand and intrastrand cross-links with severe toxicity. This is the largest study that focused on replicating findings from previous pharmacogenetics articles. We found several associations of previously investigated SNPs with severe platinum-induced toxicity. Our findings may offer comprehensive pharmacogenetic information for platinum-induced toxicity. Future efforts should focus on conducting large, well-defined studies and functional assays to confirm the associations.
